P2RX7 and cancer: Increasing evidence supports the role of purinergic signaling through P2 purinergic receptors in regulating normal bone turnover, but also seems to play a role in the pathophysiology of a range of bone diseases including postmenopausal osteoporosis, immune-mediated bone loss, and cancer-induced bone disease as well as in bone-pain.